Literature DB >> 27251484

Syndromes that Mimic an Excess of Mineralocorticoids.

Chiara Sabbadin1, Decio Armanini2.   

Abstract

Pseudohyperaldosteronism is characterized by a clinical picture of hyperaldosteronism with suppression of renin and aldosterone. It can be due to endogenous or exogenous substances that mimic the effector mechanisms of aldosterone, leading not only to alterations of electrolytes and hypertension, but also to an increased inflammatory reaction in several tissues. Enzymatic defects of adrenal steroidogenesis (deficiency of 17α-hydroxylase and 11β-hydroxylase), mutations of mineralocorticoid receptor (MR) and alterations of expression or saturation of 11-hydroxysteroid dehydrogenase type 2 (apparent mineralocorticoid excess syndrome, Cushing's syndrome, excessive intake of licorice, grapefruits or carbenoxolone) are the main causes of pseudohyperaldosteronism. In these cases treatment with dexamethasone and/or MR-blockers is useful not only to normalize blood pressure and electrolytes, but also to prevent the deleterious effects of prolonged over-activation of MR in epithelial and non-epithelial tissues. Genetic alterations of the sodium channel (Liddle's syndrome) or of the sodium-chloride co-transporter (Gordon's syndrome) cause abnormal sodium and water reabsorption in the distal renal tubules and hypertension. Treatment with amiloride and thiazide diuretics can respectively reverse the clinical picture and the renin aldosterone system. Finally, many other more common situations can lead to an acquired pseudohyperaldosteronism, like the expansion of volume due to exaggerated water and/or sodium intake, and the use of drugs, as contraceptives, corticosteroids, β-adrenergic agonists and FANS. In conclusion, syndromes or situations that mimic aldosterone excess are not rare and an accurate personal and pharmacological history is mandatory for a correct diagnosis and avoiding unnecessary tests and mistreatments.

Entities:  

Keywords:  11 Hydroxysteroid dehydrogenase type 2; Aldosterone; Apparent mineralocorticoid excess syndrome; Deoxycorticosterone; Hypertension; Licorice; Mineralocorticoid receptor; Pseudohyperaldosteronism

Mesh:

Substances:

Year:  2016        PMID: 27251484     DOI: 10.1007/s40292-016-0160-5

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  20 in total

Review 1.  Grapefruit juice inhibits 11beta-hydroxysteroid dehydrogenase in vivo, in man.

Authors:  Mario Palermo; Decio Armanini; Giuseppe Delitala
Journal:  Clin Endocrinol (Oxf)       Date:  2003-07       Impact factor: 3.478

2.  Pseudohyperaldosteronism from liquorice-containing laxatives.

Authors:  M Scali; C Pratesi; M C Zennaro; V Zampollo; D Armanini
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

Review 3.  Progress in molecular-genetic studies on congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency.

Authors:  Li-Qiang Zhao; Su Han; Hao-Ming Tian
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

Review 4.  Ubiquitylation and control of renal Na+ balance and blood pressure.

Authors:  Caroline Ronzaud; Olivier Staub
Journal:  Physiology (Bethesda)       Date:  2014-01

5.  Further studies on the mechanism of the mineralocorticoid action of licorice in humans.

Authors:  D Armanini; S Lewicka; C Pratesi; M Scali; M C Zennaro; S Zovato; C Gottardo; M Simoncini; A Spigariol; V Zampollo
Journal:  J Endocrinol Invest       Date:  1996-10       Impact factor: 4.256

6.  Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.

Authors:  D S Geller; A Farhi; N Pinkerton; M Fradley; M Moritz; A Spitzer; G Meinke; F T Tsai; P B Sigler; R P Lifton
Journal:  Science       Date:  2000-07-07       Impact factor: 47.728

7.  Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes.

Authors:  Lorenzo A Calò; Francesca Zaghetto; Elisa Pagnin; Paul A Davis; Paola De Mozzi; Paola Sartorato; Giuseppe Martire; Cristina Fiore; Decio Armanini
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

8.  Some considerations about evolution of idiopathic primary aldosteronism.

Authors:  D Armanini; C Fiore
Journal:  J Endocrinol Invest       Date:  2009-07       Impact factor: 4.256

9.  Characterization of aldosterone binding sites in circulating human mononuclear leukocytes.

Authors:  D Armanini; T Strasser; P C Weber
Journal:  Am J Physiol       Date:  1985-03

10.  Detection of mutations in KLHL3 and CUL3 in families with FHHt (familial hyperkalaemic hypertension or Gordon's syndrome).

Authors:  Mark Glover; James S Ware; Amanda Henry; Martin Wolley; Roddy Walsh; Louise V Wain; Shengxin Xu; William G Van't Hoff; Martin D Tobin; Ian P Hall; Stuart Cook; Richard D Gordon; Michael Stowasser; Kevin M O'Shaughnessy
Journal:  Clin Sci (Lond)       Date:  2014-05       Impact factor: 6.124

View more
  4 in total

1.  Evaluation and implications of salt intake and excretion.

Authors:  Decio Armanini; Luciana Bordin; Gabriella Donà; Alessandra Andrisani; Guido Ambrosini; Marco Boscaro; Chiara Sabbadin
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-26       Impact factor: 3.738

2.  Considerations for the Assessment of Salt Intake by Urinary Sodium Excretion in Hypertensive Patients.

Authors:  Decio Armanini; Luciana Bordin; Alessandra Andrisani; Guido Ambrosini; Gabriella Donà; Chiara Sabbadin
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-07-25       Impact factor: 3.738

Review 3.  The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Int J Mol Sci       Date:  2018-02-11       Impact factor: 5.923

4.  Role of adrenocorticotropic hormone in essential hypertension and primary aldosteronism.

Authors:  Decio Armanini; Alessandra Andrisani; Guido Ambrosini; Luciana Bordin; Chiara Sabbadin
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-12-05       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.